Molecular genetics of peripheral T-cell lymphomas

Pier Paolo Piccaluga, Valentina Tabanelli, Stefano A. Pileri

Research output: Contribution to journalArticle

Abstract

Peripheral T-cell lymphomas (PTCL) are rare neoplasms that in most instances respond poorly to conventional chemotherapies. Four varieties-PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), ALK+ anaplastic T-cell lymphoma (ALCL), and ALK- ALCL-account for about 60 % of them. Their classification is difficult because of the wide spectrum of morphologic features and the lack of robust immunohistochemical markers. Thus, high-throughput technologies can importantly contribute to their better understanding. In particular, gene expression profiling has cleared the borders among PTCL/NOS, ALK- ALCL and AITL. In fact, gene signatures have been developed even from formalin-fixed paraffin-embedded tissue samples that definitely distinguish one tumor from the other(s). This has important practical implications: for instance on routine diagnostics PTCL/NOS expressing CD30 can be easily confused with ALK- ALCL, but has a much worse prognosis. Therefore, the clear-cut distinction between the two conditions is pivotal to understand the results of ongoing trials with Brentuximab Vedotin, targeting the CD30 molecule. Besides improving the diagnosis, molecular studies have provided the rationale for the usage of novel drugs in the setting of PTCLs, such as ALK inhibitors in ALK+ ALCL, anti-angiogenetic drugs in AITL, and tyrosine kinase inhibitors in PTCL/NOS and ALK+ and ALK- ALCLs.

Original languageEnglish
Pages (from-to)219-226
Number of pages8
JournalInternational Journal of Hematology
Volume99
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Peripheral T-Cell Lymphoma
T-Cell Lymphoma
Molecular Biology
Gene Expression Profiling
Pharmaceutical Preparations
Paraffin
Protein-Tyrosine Kinases
Formaldehyde
Neoplasms
Technology
Drug Therapy

Keywords

  • Gene expression profiling
  • High-throughput sequencing
  • Peripheral T-cell lymphomas
  • Tyrosine kinases

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Molecular genetics of peripheral T-cell lymphomas. / Piccaluga, Pier Paolo; Tabanelli, Valentina; Pileri, Stefano A.

In: International Journal of Hematology, Vol. 99, No. 3, 2014, p. 219-226.

Research output: Contribution to journalArticle

Piccaluga, Pier Paolo ; Tabanelli, Valentina ; Pileri, Stefano A. / Molecular genetics of peripheral T-cell lymphomas. In: International Journal of Hematology. 2014 ; Vol. 99, No. 3. pp. 219-226.
@article{a18a24162bfa44849b92b2defa30778e,
title = "Molecular genetics of peripheral T-cell lymphomas",
abstract = "Peripheral T-cell lymphomas (PTCL) are rare neoplasms that in most instances respond poorly to conventional chemotherapies. Four varieties-PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), ALK+ anaplastic T-cell lymphoma (ALCL), and ALK- ALCL-account for about 60 {\%} of them. Their classification is difficult because of the wide spectrum of morphologic features and the lack of robust immunohistochemical markers. Thus, high-throughput technologies can importantly contribute to their better understanding. In particular, gene expression profiling has cleared the borders among PTCL/NOS, ALK- ALCL and AITL. In fact, gene signatures have been developed even from formalin-fixed paraffin-embedded tissue samples that definitely distinguish one tumor from the other(s). This has important practical implications: for instance on routine diagnostics PTCL/NOS expressing CD30 can be easily confused with ALK- ALCL, but has a much worse prognosis. Therefore, the clear-cut distinction between the two conditions is pivotal to understand the results of ongoing trials with Brentuximab Vedotin, targeting the CD30 molecule. Besides improving the diagnosis, molecular studies have provided the rationale for the usage of novel drugs in the setting of PTCLs, such as ALK inhibitors in ALK+ ALCL, anti-angiogenetic drugs in AITL, and tyrosine kinase inhibitors in PTCL/NOS and ALK+ and ALK- ALCLs.",
keywords = "Gene expression profiling, High-throughput sequencing, Peripheral T-cell lymphomas, Tyrosine kinases",
author = "Piccaluga, {Pier Paolo} and Valentina Tabanelli and Pileri, {Stefano A.}",
year = "2014",
doi = "10.1007/s12185-014-1522-1",
language = "English",
volume = "99",
pages = "219--226",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Molecular genetics of peripheral T-cell lymphomas

AU - Piccaluga, Pier Paolo

AU - Tabanelli, Valentina

AU - Pileri, Stefano A.

PY - 2014

Y1 - 2014

N2 - Peripheral T-cell lymphomas (PTCL) are rare neoplasms that in most instances respond poorly to conventional chemotherapies. Four varieties-PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), ALK+ anaplastic T-cell lymphoma (ALCL), and ALK- ALCL-account for about 60 % of them. Their classification is difficult because of the wide spectrum of morphologic features and the lack of robust immunohistochemical markers. Thus, high-throughput technologies can importantly contribute to their better understanding. In particular, gene expression profiling has cleared the borders among PTCL/NOS, ALK- ALCL and AITL. In fact, gene signatures have been developed even from formalin-fixed paraffin-embedded tissue samples that definitely distinguish one tumor from the other(s). This has important practical implications: for instance on routine diagnostics PTCL/NOS expressing CD30 can be easily confused with ALK- ALCL, but has a much worse prognosis. Therefore, the clear-cut distinction between the two conditions is pivotal to understand the results of ongoing trials with Brentuximab Vedotin, targeting the CD30 molecule. Besides improving the diagnosis, molecular studies have provided the rationale for the usage of novel drugs in the setting of PTCLs, such as ALK inhibitors in ALK+ ALCL, anti-angiogenetic drugs in AITL, and tyrosine kinase inhibitors in PTCL/NOS and ALK+ and ALK- ALCLs.

AB - Peripheral T-cell lymphomas (PTCL) are rare neoplasms that in most instances respond poorly to conventional chemotherapies. Four varieties-PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), ALK+ anaplastic T-cell lymphoma (ALCL), and ALK- ALCL-account for about 60 % of them. Their classification is difficult because of the wide spectrum of morphologic features and the lack of robust immunohistochemical markers. Thus, high-throughput technologies can importantly contribute to their better understanding. In particular, gene expression profiling has cleared the borders among PTCL/NOS, ALK- ALCL and AITL. In fact, gene signatures have been developed even from formalin-fixed paraffin-embedded tissue samples that definitely distinguish one tumor from the other(s). This has important practical implications: for instance on routine diagnostics PTCL/NOS expressing CD30 can be easily confused with ALK- ALCL, but has a much worse prognosis. Therefore, the clear-cut distinction between the two conditions is pivotal to understand the results of ongoing trials with Brentuximab Vedotin, targeting the CD30 molecule. Besides improving the diagnosis, molecular studies have provided the rationale for the usage of novel drugs in the setting of PTCLs, such as ALK inhibitors in ALK+ ALCL, anti-angiogenetic drugs in AITL, and tyrosine kinase inhibitors in PTCL/NOS and ALK+ and ALK- ALCLs.

KW - Gene expression profiling

KW - High-throughput sequencing

KW - Peripheral T-cell lymphomas

KW - Tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=84897373303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897373303&partnerID=8YFLogxK

U2 - 10.1007/s12185-014-1522-1

DO - 10.1007/s12185-014-1522-1

M3 - Article

C2 - 24481943

AN - SCOPUS:84897373303

VL - 99

SP - 219

EP - 226

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -